New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
07:50 EDTGWPHGW Pharmaceuticals shares attractive ahead of data, says Leerink
After meeting with management, Leerink says is continue to view shares of GW Pharmaceuticals as attractive here ahead of additional Epidiolex data readouts and the commencement of pivotal trials in the second half of 2014. The firm reiterates an Outperform rating on the stock with a $110 price target.
News For GWPH From The Last 14 Days
Check below for free stories on GWPH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
11:40 EDTGWPHOptions with increasing implied volatility
Subscribe for More Information
September 25, 2014
10:24 EDTGWPHGW Pharmaceuticals management to meet with Leerink
Subscribe for More Information
September 22, 2014
07:51 EDTGWPHGW Pharmaceuticals could trade up 25% on data, says Leerink
Leerink believes shares of GW Pharmaceuticals could trade up 25% should the Epidiolex data in pediatric epilepsy show a seizure reduction materially greater than 44%. The data is expected in the second half of 2014. The firm says shares could trade up 15% higher on a reduction at or close to 40%, or 15% lower if the mean reduction is in the 20%-30% range. Leerink is bullish ahead of the data readout after reviewing the cannabidiol epilepsy literature and previous anti-epileptic drug trials. It has an Outperform rating on shares of GW Pharmaceuticals with a $110 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use